Back to Search Start Over

CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma

Authors :
Sherrif F. Ibrahim
Benedetta Campanelli
Morganna Freeman
Medha Sasane
Sunandana Chandra
Michael L. Andria
Guilherme Rabinowits
Emily S. Ruiz
Jigar Desai
Nikhil I. Khushalani
Alex Seluzhytsky
Zhen Chen
Chieh I. Chen
Michael R. Migden
Source :
Future Oncology. 16:11-19
Publication Year :
2020
Publisher :
Future Medicine Ltd, 2020.

Abstract

In 2018, cemiplimab-rwlc became the first systemic treatment approved by the US FDA for patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. In 2019, conditional approvals were granted by Health Canada and the European Commission for the same indications. Limited data exist pertaining to the clinical characteristics, disease progression and survivorship of patients with advanced CSCC in real-world clinical practice. CemiplimAb-rwlc Survivorship and Epidemiology (CASE) is a prospective Phase IV, noninterventional, survivorship and epidemiology study that will enroll patients with advanced CSCC who have recently initiated or who plan to receive cemiplimab in a real-world setting. Trial registration number: NCT03836105.

Details

ISSN :
17448301 and 14796694
Volume :
16
Database :
OpenAIRE
Journal :
Future Oncology
Accession number :
edsair.doi.dedup.....fa80e33fd56082496d9717f80c2dbbfc
Full Text :
https://doi.org/10.2217/fon-2019-0762